The global hereditary angioedema therapeutic market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.82% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 3.1 Billion |
Market Forecast in 2033
|
USD 5.9 Billion |
Market Growth Rate 2025-2033 | 6.82% |
Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to a deficiency of a blood protein. It also leads to fluid leakage due to the constant accumulation of liquids outside the veins of hands, feet, intestinal wall, genitals, face, tongue, and larynx. At present, there is a rise in the demand for hereditary angioedema therapeutics due to the growing advancements in novel therapeutics across the globe.
There is presently a considerable increase in the prevalence of HAE among individuals due to a lack of C1 protein. As a result, there is a rise in the demand for HAE therapeutics around the world. This, along with the growing awareness among the masses about the treatment of HAE, represents one of the key factors driving the market. Moreover, key market players are extensively investing in research and development (R&D) activities to enhance orphan drug development. This, coupled with the escalating demand for subcutaneous injections that are highly effective in administering medications, such as insulin, morphine, diacetylmorphine and goserelin, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to facilitate faster diagnosis and provide optimal standards of treatment and care to patients. In line with this, rising incidences of genetic mutations leading to the disorder are positively influencing the market. Besides this, the escalating demand for preventive medical care to avoid future illness and treatment is offering lucrative growth opportunities to industry investors. Apart from this, the burgeoning healthcare industry is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hereditary angioedema therapeutic market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, drug class, treatment type, route of administration and end user.
Breakup by Type:
Breakup by Drug Class:
Breakup by Treatment Type:
Breakup by Route of Administration:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Type, Drug Class, Treatment Type, Route of Administration, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
We expect the global hereditary angioedema therapeutic market to exhibit a CAGR of 6.82% during 2025-2033.
The high prevalence of HAE among individuals owing to the lack of C1 protein, coupled with the growing cases of genetic mutations, are primarily driving the global hereditary angioedema therapeutic market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective hereditary angioedema treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for hereditary angioedema therapeutics.
Based on the type, the global hereditary angioedema therapeutic market can be divided into type I hereditary angioedema, type II hereditary angioedema, and type III hereditary angioedema. Currently, type I hereditary angioedema holds the majority of the global market share.
Based on the drug class, the global hereditary angioedema therapeutic market has been segregated into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Among these, C1-esterase inhibitor currently accounts for the largest market share.
Based on the treatment type, the global hereditary angioedema therapeutic market can be categorized into prophylaxis treatment and on-demand treatment. Currently, on-demand treatment exhibits a clear dominance in the market.
Based on the route of administration, the global hereditary angioedema therapeutic market has been segmented into intravenous, subcutaneous, and oral, where intravenous currently accounts for the largest market share.
Based on the end user, the global hereditary angioedema therapeutic market can be bifurcated into hospitals, clinics, home healthcare, and others. Currently, hospitals hold the majority of the total market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global hereditary angioedema therapeutic market include Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A., and Takeda Pharmaceutical Company Limited.